PCI Biotech announces positive feedback regarding a patent application in vaccination and immunotherapy

Lysaker, 06 March 2015 – PCI Biotech announced today that it has received a positive international search report and written opinion regarding a patent application on the use of PCI Biotech’s proprietary technology photochemical internalization (PCI) in vaccination and immunotherapy. The European Patent Office (EPO), acting as the International Searching Authority, provided a written opinion indicating that the most important claims of the patent application have "novelty" and "inventive step" and that they also have "industrial applicability". While this opinion is not binding on national patent offices, it does provide a positive indication of the allowability of the claims. The patent application covers the use of the PCI technology in combination with a very important group of immune enhancing substances and may give PCI Biotech at least 20 years broad protection for the use of the PCI technology with many of the therapeutic cancer vaccines that are under development.

Per Walday, CEO, said: "Given PCI Biotech’s commitment to developing a robust intellectual property position in cancer immunotherapy, we are very pleased to receive this news. This is a field in rapid development and our preclinical results suggest a high potential of PCI Biotech’s proprietary technology in this area. The patent estate we are building in key areas of immunotherapy is important in order to be well positioned for future out-licensing and commercialization of our CTL-induction technology".